Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2014 1
2015 1
2016 1
2017 1
2019 1
2020 3
Text availability
Article attribute
Article type
Publication date

Search Results

8 results
Results by year
Filters applied: . Clear all
Page 1
Intra-venous bevacizumab in hereditary hemorrhagic telangiectasia (HHT): A retrospective study of 46 patients.
Guilhem A, Fargeton AE, Simon AC, Duffau P, Harle JR, Lavigne C, Carette MF, Bletry O, Kaminsky P, Leguy V, Lerolle N, Roux D, Lambert M, Chinet T, Bonnet D, Dupuis-Girod S, Rivière S. Guilhem A, et al. Among authors: Fargeton AE. PLoS One. 2017 Nov 30;12(11):e0188943. doi: 10.1371/journal.pone.0188943. eCollection 2017. PLoS One. 2017. PMID: 29190827 Free PMC article. Clinical Trial.
Efficacy of TIMOLOL nasal spray as a treatment for epistaxis in hereditary hemorrhagic telangiectasia. A double-blind, randomized, placebo-controlled trial.
Dupuis-Girod S, Pitiot V, Bergerot C, Fargeton AE, Beaudoin M, Decullier E, Bréant V, Colombet B, Philouze P, Faure F, Letievant JC. Dupuis-Girod S, et al. Among authors: Fargeton AE. Sci Rep. 2019 Aug 19;9(1):11986. doi: 10.1038/s41598-019-48502-9. Sci Rep. 2019. PMID: 31427745 Free PMC article.
Dose - response relationship of bevacizumab in hereditary hemorrhagic telangiectasia.
Azzopardi N, Dupuis-Girod S, Ternant D, Fargeton AE, Ginon I, Faure F, Decullier E, Roux A, Carette MF, Gilbert-Dussardier B, Hatron PY, Lacombe P, Leguy-Seguin V, Rivière S, Corre R, Bailly S, Paintaud G. Azzopardi N, et al. Among authors: Fargeton AE. MAbs. 2015;7(3):630-7. doi: 10.1080/19420862.2015.1022693. MAbs. 2015. PMID: 25751241 Free PMC article.
Effect of Bevacizumab Nasal Spray on Epistaxis Duration in Hereditary Hemorrhagic Telangectasia: A Randomized Clinical Trial.
Dupuis-Girod S, Ambrun A, Decullier E, Fargeton AE, Roux A, Bréant V, Colombet B, Rivière S, Cartier C, Lacombe P, Chinet T, Blivet S, Blondel JH, Gilbert-Dussardier B, Dufour X, Michel J, Harle JR, Dessi P, Faure F. Dupuis-Girod S, et al. Among authors: Fargeton AE. JAMA. 2016 Sep 6;316(9):934-42. doi: 10.1001/jama.2016.11387. JAMA. 2016. PMID: 27599328 Clinical Trial.
ELLIPSE Study: a Phase 1 study evaluating the tolerance of bevacizumab nasal spray in the treatment of epistaxis in hereditary hemorrhagic telangiectasia.
Dupuis-Girod S, Ambrun A, Decullier E, Samson G, Roux A, Fargeton AE, Rioufol C, Schwiertz V, Disant F, Chapuis F, Donazzolo Y, Paintaud G, Edery P, Faure F. Dupuis-Girod S, et al. Among authors: Fargeton AE. MAbs. 2014 May-Jun;6(3):794-9. doi: 10.4161/mabs.28025. Epub 2014 Jan 30. MAbs. 2014. PMID: 24481211 Free PMC article. Clinical Trial.
Efficacy and Safety of a 0.1% Tacrolimus Nasal Ointment as a Treatment for Epistaxis in Hereditary Hemorrhagic Telangiectasia: A Double-Blind, Randomized, Placebo-Controlled, Multicenter Trial.
Dupuis-Girod S, Fargeton AE, Grobost V, Rivière S, Beaudoin M, Decullier E, Bernard L, Bréant V, Colombet B, Philouze P, Bailly S, Faure F, Hermann R. Dupuis-Girod S, et al. Among authors: Fargeton AE. J Clin Med. 2020 Apr 26;9(5):1262. doi: 10.3390/jcm9051262. J Clin Med. 2020. PMID: 32357559 Free PMC article.
Feedback